望石智慧 (StoneWise)
2 known investors
Stonewise develops MolVado, an AI-driven platform for small-molecule drug discovery that uses multimodal 3D molecular generation models to design candidate molecules based on protein pockets, reference fragments, or pharmacophores. The platform supports the full DMTA (Design-Make-Test-Analyze) cycle, combining generative AI with computational chemistry validation tools and a compound library backed by CRO synthesis services for pharmaceutical R&D teams.
Investors · 2
Frequently asked questions
- What does 望石智慧 (StoneWise) do?
- Stonewise develops MolVado, an AI-driven platform for small-molecule drug discovery that uses multimodal 3D molecular generation models to design candidate molecules based on protein pockets, reference fragments, or pharmacophores. The platform supports the full DMTA (Design-Make-Test-Analyze) cycle, combining generative AI with computational chemistry validation tools and a compound library backed by CRO synthesis services for pharmaceutical R&D teams.
- Who are 望石智慧 (StoneWise)'s investors?
- 望石智慧 (StoneWise)'s investors include Xiang He Capital, Linear Capital.